Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    Jump to

    • Not looking at M&A as growth opportunity, would like to grow organically: Glenmark

    • Cash from out-licensing GBR 830 will be used for repayment of debt: Glenmark

    • Govt needs to be a strong enabler in pharma sector: Experts

    • New launches to drive earnings growth in FY18 & FY19: Glenmark

    • Aurobindo's Hyd unit getting form 483 a non-event: Surajit Pal

    • See EBITDA margins at 25% over 10 years: Glenmark CMD

    • Expect better performance from core US biz in Q3: Glenmark

    • New products, regulatory approvals to drive growth for Glenmark

    • Awaiting $45 million from Venezuelan govt: Glenmark Pharma

    • Aim is to prevent rampant use of antibiotics: P Lilladher

    • See 18-20% growth, 10-12 product launches in US: Glenmark

    • Sun's margins may reduce to 30-32% post merger: Surajit Pal

    • India Q2 biz has outperformed; maintain guidance: Glenmark

    • GBR 1302 could be an out-licencing opportunity: Glenmark

    • Glenmark: Environment challenging, see 20% growth in FY14

      Pharma major Glenmark says the operating environment is challenging given the slowdown in India and longer time taken by the US drug regulator for product approvals. It is expecting a 20 percent revenue growth in FY14.

    • Glenmark to get USD 9 mn upfront: CEO; stk at 52-wk high

      Shares of Glenmark Pharmaceuticals rose over 2 percent to a 52-week high of Rs 512.65 on Monday morning following its agreement with Forest Laboratories on a collaboration for development of inhibitors to treat chronic inflammatory conditions, including pain.

    • May not see 35% growth in H1 sustaining in H2: Glenmark

      Glenn Saldanha, MD & CEO, Glenmark said the pharma major is growth at the rate of 30% in the Indian market and is confident of maintaining margins ahead.

    • Launches in FY13 to boost growth in Indian market: Glenmark

      Aided by malarone and cutivate generic, the US business of Glenmark Pharma saw recovery in the fourth quarter of FY12. In an interview with CNBC-TV18, Glenn Saldanha, MD & CEO of Glenmark said, the company expects its domestic market to outperform industry in FY13.

    • Glenmark Pharma sees its India business growing at 23-24%

      Glenn Saldanha, managing director and CEO of Glenmark Pharmaceuticals, in an interview with CNBC-TV18's Udayan Mukherjee and Mitali Mukherjee, said that its business in India is growing at 23-24%, while its business in US is expected to grow 25% in FY12.

    • Glenmark confident of US growth despite Tarka issue

      In an interview with CNBC-TV18, Glenn Saldanha, managing director and chief executive officer of Glenmark Pharmaceuticals said,"Tarka is not a major contributor any more to the topline for the US business."

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347